Expanded Access to Gallium Maltolate (GaM)

NCT06404034 | Unknown

• 1 other identifier: IB-EAP-100
• Study Type: expanded_access
• Target: N/A
• Locations: 1 country
• Sites: 4

Brief Summary

The objective of this program is to provide GaM for compassionate use in patients with relapsed/refractory histologic or molecular glioblastoma who have exhausted available treatments. The population of this program is adult patients aged greater than or equal to 18 years with a diagnosis of relapsed/refractory histologic or molecular glioblastoma, according to the WHO 2021 diagnostic criteria. Molecular glioblastoma is characterized as an IDH-wildtype diffuse and astrocytic glioma in adults if there is microvascular proliferation or necrosis or TERT promoter mutation or EGFR gene amplification or +7/-10 chromosome copy number changes

Conditions

Glioblastoma; Refractory Glioblastoma; Glioblastoma Multiforme

Keywords

glioblastoma; refractory glioblastoma

Interventions

Gallium Maltolate DRUG

GaM will be provided as 500 mg capsules and will be self-administered once daily by mouth at the assigned dose level on a 28-day cycle (one cycle is 28 days) on an empty stomach. GaM should be taken at least 60 minutes before a meal and at least two hours after a meal. Liquids are allowed

Also known as: GaM

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patient has relapsed/refractory histologic or molecular glioblastoma who, in the opinion of the treating physician, may benefit from treatment from GaM.
• Male or female patient aged ≥ 18 years.
• In the opinion of the treating physician, the patient has adequate organ function to tolerate GaM.
• Patient must be able to swallow and retain orally administered medication.
• For females of childbearing potential, negative urinary or serum pregnancy test.
• Patients must be willing to highly effective contraception for both male and female patients throughout the treatment and for at least 4 months after last treatment administration.
• Toxicities related to any prior treatments are either stable, stable on supportive therapy, resolved, or in the opinion of the treating physician, clinically non-significant.
• Ability to understand a written informed consent document, and the willingness to sign it by the patient or legally authorized patient representative (LAR) or guardian.
• Informed consent obtained for the XCELSIOR longitudinal outcomes registry (NCT03793088)

You may not qualify if:

• Patient is already participating in or is able to enroll in a clinical trial of GaM.
• Patient has received systemic therapy with an investigational agent within 5 half-lives or 14 days prior to starting GaM treatment, whichever is shorter.
• Patients completing radiotherapy treatment less than 14 days prior to planned study treatment initiation.
• Patient is taking oral iron supplements or iron chelators.
• Current evidence of uncontrolled, significant intercurrent illness that would, in the treating physician's judgment, contraindicate the patient's treatment with GaM due to safety concerns.
• Patients who, in the opinion of the treating physician, have not fully recovered from recent major surgery to a sufficient extent to tolerate treatment with GaM.
• Known hypersensitivity to GaM or any component in its formulation.
• Patients taking prohibited medications as described in the current Investigator's Brochure.
• Patient is pregnant or actively breastfeeding

Sponsors & Collaborators

• xCures: collaborator
• Imaging Biometrics, LLC: lead

Study Sites (4)

University of Miami Sylvester Comprehensive Cancer Center

Miami, Florida, 33136, United States

Location

Cancer Partners of Nebraska

Lincoln, Nebraska, 68516, United States

Location

Northwell Health

New York, New York, 10075, United States

Location

University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, 27599, United States

Location

MeSH Terms

Conditions

Glioblastoma

Interventions

gallium maltolate

Condition Hierarchy (Ancestors)

Astrocytoma; Glioma; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue

Study Design

• Study Type: expanded access
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 2, 2024
• First Posted: May 8, 2024
• Last Updated: March 4, 2026

Record last verified: 2026-03

Locations

US (4)